Researchers at McMaster University in Hamilton, Ontario, have discovered that a naturally occurring hormone that suppresses ...
Genglycos is a one-time infusion to replace the G6PC gene in patients with glycogen storage disease type Ia, a rare genetic ...
Randomized SNAP disbursement timing across the first 10 business days enabled a quasi-experimental test of financial scarcity ...
Garetosmab targets Activin A, a key driver of ectopic bone formation in FOP, with preclinical evidence that pathway ...
"FSGS Payer Policy: Aligning Coverage with the Sparsentan Label" takes up the gap between DUPLEX's enrollment criteria and the broader population the FDA label actually covers.
In "Communicating with Payers: Practical Guidance for Sparsentan Access in FSGS," the panel closes the series with practical ...
A small, stretch-insensitive mucosal afferent population near the urothelial lining serves as an infection/inflammation ...
Continuing the Managed Healthcare Executive Between the Lines series, moderator Philip Mease, MD, of Swedish Medical Center, ...
A 10-year agreement expands a 35+ year collaboration that has generated 100+ research projects and 70 peer-reviewed publications, reinforcing a joint innovation and evidence-generation agenda. Fleet ...
Medicaid expansion was linked with improved insurance coverage, early-stage diagnosis and overall survival among patients ...
Patrick Gleason, Pharm.D., assistant vice president of health outcomes at Prime Therapeutics, has become one of the most ...
Earlier in hypertension treatment, baxdrostat and lorundrostat were comparable or inferior to amlodipine, undermining ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results